THERAPY DOSSIER · th-760ed498d5ee

TCB-2 [(4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide]

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28844001 ↗2017Mixed findings

Activation of 5-HT Receptors Restores KCC2 Function and Reduces Neuropathic Pain after Spinal Cord Injury.

RatSpinal cord injuryHemisection / partialFemaleAcute administration after establishment of injury-induced hyperalgesia

Model: Thoracic spinal cord hemisection (central neuropathic pain) and spared nerve injury of the sciatic nerve (peripheral neuropathic pain)

TCB-2 reduced mechanical and thermal hyperalgesia after spinal cord injury in association with increased dorsal horn membrane KCC2 expression, and this analgesia was prevented by intrathecal DIOA. The same treatment did not attenuate spared nerve injury-induced neuropathic pain despite a slight inc…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…